ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs), focusing on transforming treatment for patients with hematologic malignancies and solid tumors [2] - The company is based in Lausanne, Switzerland, with operations in London, the San Francisco Bay Area, and New Jersey [3] Recent Developments - ADC Therapeutics will host a virtual Research Investor Event on April 9, 2024, featuring presentations from the CEO and Chief Scientific Officer, discussing updates on their exatecan-based ADC platform [1] - The company's CD19-directed ADC, ZYNLONTA (loncastuximab tesirine-lpyl), has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] Product Pipeline - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy, alongside multiple ADCs in ongoing clinical and preclinical development [2]